转移性去势抵抗性前列腺癌中[177Lu]Lu-PSMA-I&T放射配体治疗再挑战的疗效与安全性
该回顾性研究纳入18例初始[177Lu]Lu-PSMA放射配体治疗(PRLT)应答后新进展的转移性去势抵抗性前列腺癌(mCRPC)患者,评估再挑战[177Lu]Lu-PSMA-I&T的安全性和结局。再挑战后44%患者达PSA50%应答,56%达PSA疾病控制;初始治疗中位总生存期(OS)为29个月,再挑战为11个月。作者认为再挑战可能延长选定患者的生存,安全性可接受。
要点
- 再挑战PRLT后44%患者达PSA50%应答,56%达PSA疾病控制。
- 再挑战期间无危及生命的G4不良事件,G3事件包括贫血、血小板减少和肾衰竭各1例。
- 初始治疗中位OS为29个月,再挑战中位OS为11个月。
核心结论
- 超过半数患者从再挑战PRLT中获益。
- 作者分析提示再挑战可能延长选定患者的生存,且安全性可接受。
研究设计与样本
- 回顾性纳入18例初始PRLT应答后新进展的mCRPC患者,均经[68Ga]Ga-PSMA-11 PET/CT确认PSMA阳性转移且ECOG体能状态0-1。
- 再挑战[177Lu]Lu-PSMA-I&T,不良事件按CTCAE v5.0分级,PSA应答按PCWG3标准评估,影像应答按adapted PERCIST v1.0评估。
主要发现
- 初始治疗中位5周期(范围4-7),再挑战距初始治疗中位9个月(范围3-13),每例再挑战中位4周期(范围2-7),中位累积活度26.1 GBq。
- 再挑战后最佳PSA50%应答率为44%,末周期PSA疾病控制率为56%。
- 12/18例患者再分期影像中,6/12(50%)疾病控制(部分缓解/稳定),1/12混合应答,5/12进展。
- 中位随访25个月(范围14-44),10例死亡、7例存活、1例失访;初始治疗中位OS为29个月(95%CI 14.3-43.7),再挑战中位OS为11个月(95%CI 8.1-13.8)。
关键数值与推荐
- PSA50%应答定义为PSA较基线下降≥50%,按PCWG3标准评估。
- 影像应答按adapted PERCIST v1.0分类为部分缓解、稳定、混合应答或进展。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The purpose of this study was to evaluate the safety and outcome of rechallenge [177Lu]Lu-PSMA-I&T in newly progressed mCRPC patients after response to initial [177Lu]Lu-PSMA radioligand therapy (PRLT). METHODS: We retrospectively included 18 patients who underwent rechallenge with [177Lu]Lu-PSMA-I&T. All patients presented with (i) newly progressed disease after response to initial PRLT; (ii) a [68Ga]Ga-PSMA-11 PET/CT confirming the presence of PSMA-positive metastases; iii) ECOG performance status 0-1. Adverse events were graded according to CTCAE v5.0. Response was assessed by PSA and classified according to PCWG3 recommendations. For patients who underwent restaging with [68Ga]Ga-PSMA-11 PET/CT, imaging response was categorised according to adapted PERCIST v1.0. In patients with discordant [68Ga]Ga-PSMA-11 PET/CT and PSA, other available imaging modalities were evaluated to confirm disease status. Overall survival (OS) was calculated from the first cycle of initial PRLT and rechallenge PRLT, respectively, until last patient contact or death. RESULTS: Patients were initially treated with a median of 5 cycles (range 4-7) and were rechallenged after a median of 9 months (range 3-13). Each patient received a median of 4 (range 2-7) rechallenge cycles (median cumulative activity 26.1 GBq). None of the patients experienced life-threatening G4 adverse events during either treatment period. Grade 3 adverse events included one case of anaemia, one case of thrombocytopenia, and one case of renal failure. In 8/18 patients long-term toxicities were evaluated. Serious toxicities (≥ Grade 3) occurred in 3/8 patients (n = 1 G4 thrombocytopenia, n = 1 G4 renal failure and n = 1 pancytopenia and G4 renal failure). Best PSA50%-response was observed in 44% of patients and PSA-disease control was confirmed in 56% of patients at the last cycle. Of the 12/18 patients restaged by imaging, 6/12 (50%) patients had disease control (partial response/stable disease), 1/12 had a mixed response, and 5/12 had progression. After a median follow-up time of 25 months (range 14-44), 10 patients had died, 7 were still alive, and one patient was lost at follow-up. The median OS was 29 months (95%CI, 14.3-43.7 months) for the initial treatment and 11 months (95%CI, 8.1-13.8 months) for the first rechallenge course. CONCLUSION: More than half of patients benefit from rechallenge PRLT. Our analysis suggests that rechallenge may prolong survival in selected patients, with an acceptable safety profile.
引用
- Santo G, Di Santo G, Sviridenko A, et al. Efficacy and safety of rechallenge with [177Lu]Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2024. PMID: 39225826. doi:10.1007/s00259-024-06905-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。